Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 31, 2007 Brian Lawler	Best Stock for 2008: Gilead Sciences Shares of Gilead Sciences are a good bet for next year.
The Motley Fool July 18, 2008 Brian Lawler	Still Liking Gilead, Warts and All Don't look past a few issues, even though Gilead still has a bright future.
The Motley Fool January 28, 2009 Brian Orelli	Worth Every Penny People still need to take their antiviral medication even if the purse strings are tight, and that fact has led Gilead Sciences to putting together another great quarter.
The Motley Fool July 23, 2007 Brian Lawler	Gilead's Great Growth The drugmaker announces another great quarter of growth. Investors, take note.
The Motley Fool July 21, 2006 Brian Lawler	Gilead's Acquisitive Mood Trading at around 28 times 2006 EPS estimates, and with 40% growth expected for its HIV franchise, Gilead offers tempting value -- assuming it makes smart use of that cash sitting on the balance sheet.
The Motley Fool January 27, 2011 Brian Orelli	Gilead's Once in a Decade Quarter Gilead's revenue falls for the first time in more than a decade.
The Motley Fool October 20, 2010 Brian Orelli	What's Your Next Trick, Gilead? Just when investors had counted Gilead Sciences down for the count, it comes roaring back.
The Motley Fool April 24, 2007 Brian Lawler	Gilead's Sales Are Galloping Ahead The biotech giant announces first-quarter financial results, with its most important drugs showing no weakness. What's important for investors to figure out is whether the valuation on shares of Gilead needs to shrink or expand in order to meet its future financial fortunes.
The Motley Fool February 5, 2007 Brian Lawler	Gilead's Gold Mine In the fourth quarter, the pharmaceutical continues to rake in the cash from its top products. Investors, take note.
The Motley Fool May 19, 2004 Roger Nusbaum	Gilead Shines This biotech company looks strong because investors can relate to its products.
The Motley Fool January 27, 2010 Brian Orelli	The Virus-Killer's Killer Quarter Gilead Sciences closed out 2009 with a solid 42% increase in revenue in the fourth quarter, thanks to its HIV drugs.
AskMen.com Justin Becker	How To: Leave The Perfect Tip Some tips on tipping your waitress, cab driver, bartender and hairdresser properly.
The Motley Fool July 22, 2009 Brian Orelli	Grab Hold of This Growth Double-digit growth just keeps coming for Gilead Sciences.
The Motley Fool September 1, 2004 Rich Smith	Free Cash Flow Illusions A little accounting knowledge can be a dangerous thing. Investors need to read the SEC filings to get the real picture. Here's an example using Blockbuster, Netflix and Hollywood.
The Motley Fool November 9, 2009 Dave Mock	A Big Upgrade for Gilead Sciences The biopharmaceutical company moves up to a five star rating from Motley Fool analysts.
The Motley Fool June 3, 2010	3 Tips to Become a Better Investor Today (Fool TV) Video tips for analyzing stocks.
The Motley Fool April 22, 2009 Brian Orelli	Better Than Recession-Proof The whole health-care industry may not be recession-proof, but Gilead has shown that the right combination of drugs can lead to stellar returns -- even in a down economy.
The Motley Fool February 18, 2010 Brian Orelli	Gilead Shareholders Are Whistling a Happy Tune Full data from the company's HIV quad pill show no major issues.
The Motley Fool October 17, 2008 Brian Orelli	Gilead Sciences Killed It The virus-killer kills analysts' expectations, as well. The company blows through analysts' expectations with its third-quarter results.
The Motley Fool April 27, 2006 Anders Bylund	Blockbuster Struggles for Income Blockbuster is growing its bottom line -- through painful top-line cuts. It's time for management to take this more efficient infrastructure and pull its customers back into the stores.
The Motley Fool December 16, 2009 Brian Orelli	Gilead's Phase 3 Train Wreck Gilead Sciences' darusentan looked so promising.
The Motley Fool October 19, 2006 Brian Lawler	No Gilded Quarter for Gilead The company's recent acquisition may help it become a diversified drug giant. Investors, take note.
The Motley Fool July 19, 2010 Brian Orelli	Abbott Labs Loves Merck More Than Gilead Its HIV trial seems to suggest so.
The Motley Fool January 6, 2010 Brian Orelli	Gilead Goes It Alone ... for Now Investors jump for joy as Gilead Sciences announces what on the surface sounds like rather inconsequential data.
The Motley Fool December 22, 2004 Alyce Lomax	Blockbuster Goes for Broke The video giant lowers rental fees again. Sounds desperate and puts the light on Netflix. Further, it will help guarantee that Blockbuster's profitability will be adversely affected in the coming months, just as the company warned in early November.
The Motley Fool November 25, 2011 Dan Caplinger	Has Merck Become the Perfect Stock? Like most other pharma companies, Merck is dealing with the imminent loss of patent protection on one of its blockbuster drugs.
Fast Company October 1999 Liz Zack	How IBM Gets Unstuck The tips IBMers turn to when they hit creative roadblocks.
The Motley Fool January 4, 2007 Rick Aristotle Munarriz	Blockbuster's Millions Blockbuster lands two million paying subscribers as its Total Access service starts to stick. Now it's up to Blockbuster to prove to its shareholders that it's a workable model, too.
The Motley Fool October 21, 2009 Brian Orelli	Double-Digit Growth in a Recession The strong double-digit growth at Gilead shouldn't be much of a surprise; HIV patients need their medication even in a recession.
The Motley Fool January 31, 2006 Stephen D. Simpson	Merck Marking Time There won't be much good news for this pharmaceutical's investors until new products hit the market. If you already own Merck, you probably understand that patience will be the order of the day here.
The Motley Fool April 16, 2009 Brian Orelli	2 Virus Killers Are Better Than 1 Glaxo brings Pfizer under its HIV wing.
The Motley Fool July 21, 2010 Brian Orelli	15% Revenue Growth Is Good for Pfizer, but Not Gilead Gilead needs to reaccelerate growth.
The Motley Fool June 12, 2008 Brian Lawler	Gilead's Got the Goods As long as Gilead Sciences makes good use of its cash, its long-run future looks bright.
The Motley Fool August 4, 2005 Rick Aristotle Munarriz	Rent This Space Blockbuster's recent stumble may be a prelude to a dramatic exit from its online business. Investors, take note.
The Motley Fool May 4, 2005 David Meier	Double Your Chances If you find high-yielding stocks at low prices, you may be on your way to beating the market.
BusinessWeek September 18, 2006 Gene G. Marcial	Gilead Has "Room To Run" Most pharmaceutical companies are limping, but Gilead Sciences has sprinted.
The Motley Fool November 6, 2006 Rick Aristotle Munarriz	Chip Off the Old Blockbuster Improvement is relative at the ailing video chain. Investors, is there a glimmer of hope?
The Motley Fool July 27, 2011 Brian Orelli	Not Hypergrowth, but Good Enough Gilead posts a double-digit revenue gain.
PC World June 2002 Stephen Manes	How to Get Work Done--Beware of Tips! The best computer tips save your bacon; the worst hurt more than they help...
The Motley Fool July 30, 2004 Roger Nusbaum	Gilead Keeps Rolling Along Biotech can be a tough place to invest, but Gilead Sciences offers relative stability.
The Motley Fool April 21, 2004 W.D. Crotty	Blockbuster Looks Better The movie rental giant has a few things going its way.
The Motley Fool September 20, 2011 Brian Orelli	Phase 3 + Phase 3 = Quad Approval Will Gilead Sciences' new four-drug HIV cocktail sell?
BusinessWeek March 26, 2009 Aili McConnon	Gilead Sciences: High-Performing Pharmaceutical Gilead owes much of its success to making it easier for patients to comply with complex and uncomfortable drug regimens.
The Motley Fool March 16, 2007 Brian Lawler	Select Comfort vs. Gilead Sciences: Gilead Sciences In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2007." Investors, here is why Gilead should go all the way.
The Motley Fool April 28, 2006	Foolish Fundamentals: Same-Store Sales Every month, retailers announce their sales and comps growth. Comps are a useful gauge for investors to measure how well a company is increasing store revenues.
The Motley Fool July 24, 2007 Rick Aristotle Munarriz	Red Mailers, Blue Investors Dark days are ahead for Netflix, but things could be worse. The combined market cap of Netflix and Blockbuster is less than the $2 billion market cap that Netflix alone commanded at its peak seven months ago. Investors, take note.
The Motley Fool February 27, 2007 Brian Lawler	Gilead's Green-Lighted Drug Having a diversified drug pipeline is what makes large-cap drug stocks like Gilead so enticing, even to risk-adverse investors.
The Motley Fool February 28, 2007 Brian Lawler	Merck's Mighty Future Merck ups its 2007 financial forecast, while positive developments occur for two of its most promising new therapies.
The Motley Fool August 31, 2006 Alyce Lomax	Gap: Same Old, Same Old Same-Store Sales When it comes to August comps, Gap reports more of the same. The much-discussed -- and apparently, still highly anticipated -- turnaround is still nowhere to be seen. Investors, take note.
The Motley Fool April 19, 2006 John Bluis	Gilead's Got Cash Up to the Gills The pharmaceutical cashes in on bird-flu fears. The company's strong performance means that investors have to pay a slight premium for its shares.